Gaucher disease: Pathological mechanisms and modern management

British Journal of Haematology

Volumn 129, Issue 2, 2005, Pages 178-188

  Jmoudiak, Marina ^a   Futerman, Anthony H ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Enzyme replacement therapy; Gaucher disease; Glucocerebrosidase; Lysosomal storage disease; Macrophage

Indexed keywords

ALGLUCERASE; BETA GALACTOSIDASE; BETA GLUCOSIDASE; BISPHOSPHONIC ACID DERIVATIVE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; IMIGLUCERASE; LYSOSOME ENZYME; MIGLUSTAT; N ACETYL BETA GLUCOSAMINIDASE; SIALIDASE;

BLEEDING; BONE DISEASE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENZYME MODIFICATION; ENZYME REPLACEMENT; ENZYME SUBSTRATE; GAUCHER DISEASE; GENE THERAPY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LYSOSOME STORAGE DISEASE; MACROPHAGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SPLENECTOMY;

DIPHOSPHONATES; GAUCHER DISEASE; GENE THERAPY; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDES; HUMANS; HYPERTENSION, PULMONARY; LYSOSOMES; MACROPHAGES; NERVOUS SYSTEM DISEASES; SPLENECTOMY;

EID: 17644422131     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05351.x     Document Type: Review

References (109)

1. Abe, A., Wild, S.R., Lee, W.L. & Shayman, J.A. (2001) Agents for the treatment of glycosphingolipid storage disorders. Current Drug Metabolism, 2, 331-338.
2. Aerts, J.M., Hollak, C., Boot, R. & Groener, A. (2003) Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. Philosophical Transactions of the Royal Society of London, 358, 905-914.
3. Aghion, H. (1934) La Maladie de Gaucher dans l'Enfance. Faculte de Medecine, Paris, France.
4. Aharon-Peretz, J., Rosenbaum, H. & Gershoni-Baruch, R. (2004) Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. New England Journal of Medicine, 351, 1972-1977.
5. Allen, M.J., Myer, B.J., Khokher, A.M., Rushton, N. & Cox, T.M. (1997) Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. Quarterly Journal of Medicine, 90, 19-25.
6. Altarescu, G., Hill, S., Wiggs, E., Jeffries, N., Kreps, C., Parker, C.C., Brady, R.O., Barton, N.W. & Schiffmann, R. (2001) The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. Journal of Pediatrics, 138, 539-547.
7. Barak, V., Acker, M., Nisman, B., Kalickman, I., Abrahamov, A., Zimran, A. & Yatziv, S. (1999) Cytokines in Gaucher's disease. European Cytokine Network, 10, 205-210.
8. Barone, R., Giuffrida, G., Musso, R., Carpinteri, G. & Fiumara, A. (2000) Haemostatic abnormalities and lupus anticoagulant activity in patients with Gaucher disease type I. Journal of Inherited Metabolic Disease, 23, 387-390.
9. Beutler, E. (1994) Economic malpractice in the treatment of Gaucher's disease. American Journal of Medicine, 97, 1-2.
10. Beutler, E. & Grabowski, G.A. (2001) Gaucher Disease. In: The Metabolic and Molecular Bases of Inherited Disease, Vol. II (ed. by C.R. Scriver, W.S. Sly, B. Childs, A.L. Beaudet, D. Valle, K.W. Kinzler & B. Vogelstein), pp. 3635-3668. McGraw-Hill Inc., Columbus, USA.
11. Bitton, A., Etzell, J., Grenert, J.P. & Wang, E. (2004) Erythrophagocytosis in Gaucher cells. Archives of Pathology and Laboratory Medicine, 128, 1191-1192.
12. Bodennec, J., Pelled, D., Riebeling, C., Trajkovic, S. & Futerman, A.H. (2002) Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP: phosphocholine cytidylyltransferase by glucosylceramide. The FASEB Journal, 16, 1814-1816.
13. Boot, R.G., Verhoek, M., de Post, M., Hollak, C.E., Maas, M., Bleijlevens, B., van Breemen, M.J.., van Meurs, M., Boven, L.A., Laman, I.D., Moran, M.T., Cox, T.M. & Aerts, J.M. (2004) Marked elevation of the chemokine CCL18/P ARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood, 103, 33-39.
14. Bove, K.E., Daugherty, C. & Grabowski, G.A. (1995) Pathological findings in Gaucher disease type 2 patients following enzyme therapy. Human Pathology, 26, 1040-1045.
15. Boven, L.A., van Meurs, M., Boot, R.G., Mehta, A., Boon, L., Aerts, J.M. & Laman, J.D. (2004) Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. American Journal of Clinical Pathology, 122, 359-369.
16. Brady, R.O. (1997) Gaucher's disease: past, present and future. In: Gaucher's Disease, Vol. 10 (ed. by A. Zimran), pp. 621-634. Bailliere Tindall, London.
17. Brady, R.O. (2003) Enzyme replacement therapy: conception, chaos and culmination. Philosophical Transactions of the Royal Society of London, 358, 915-919.
18. Brautbar, A., Elstein, D., Pines, G., Abrahamov, A. & Zimran, A. (2004) Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells, Molecules and Diseases, 32, 214-217.
19. Buccoliero, R. & Futerman, A.H. (2003) The roles of ceramide and complex sphingolipids in neuronal cell function. Pharmacological Research, 47, 409-419.
20. Cabrera-Salazar, M.A., Novelli, E. & Barranger, J.A. (2002) Gene therapy for the lysosomal storage disorders. Current Opinion in Molecular Therapeutics, 4, 349-358.
21. Cenarro, A., Pocovi, M., Giraldo, P., Garcia-Otin, A.L. & Ordovas, J.M. (1999) Plasma lipoprotein responses to enzyme-replacement in Gaucher's disease. Lancet, 353, 642-643.
22. Charrow, J., Andersson, H.C., Kaplan, P., Kolodny, E.H., Mistry, P., Pastores, G., Rosenbloom, B.E., Scott, C.R., Wappner, R.S., Weinreb, N.J. & Zimran, A. (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Archives of Internal Medicine, 160, 2835-2843.
23. Charrow, J., Andersson, H.C., Kaplan, P., Kolodny, E.H., Mistry, P., Pastores, G., Prakash-Cheng, A., Rosenbloom, B.E., Scott, C.R., Wappner, R.S. & Weinreb, N.J. (2004) Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. Journal of Pediatrics, 144, 112-120.
24. Cohen, I.J., Katz, K., Kornreich, L., Horev, G., Frish, A. & Zaizov, R. (1998) Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease. Blood Cells, Molecules and Diseases, 24, 296-302.
25. Cox, T.M. (2001) Gaucher disease: Understanding the molecular pathogenesis of sphingolipidoses. Journal of Inherited Metabolic Disease, 24(Suppl. 2), 106-121.
26. Cox, T., Lachmann, R., Hollak, C., Aerts, J., van Weely, S., Hrebicek, M., Platt, F., Butters, T., Dwek, R., Moyses, C., Gow, I., Elstein, D. & Zimran, A. (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet, 355, 1481-1485.
27. Cox, T.M., Aerts, J.M., Andria, G., Beck, M., Belmatoug, N., Bembi, B., Chertkoff, R., Vom Dahl, S., Elstein, D., Erikson, A., Giralt, M., Heitner, R., Hollak, C., Hrebicek, M., Lewis, S., Mehta, A., Pastores, G.M., Rolfs, A., Miranda, M.C. & Zimran, A. (2003) The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. Journal of Inherited Metabolic Disease, 26, 513-526.
28. D'Azzo, A. (2003) Gene transfer strategies for correction of lysosomal storage disorders. Acta Haematologica, 110, 71-85.
29. Desnick, R.J. (2004) Enzyme replacement and enhancement therapies for lysosomal diseases. Journal of Inherited Metabolic Disease, 27, 385-410.
30. Desnick, R.J. & Schuchman, E.H. (2002) Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nature Reviews Genetics, 3, 954-966.
31. Dvir, H., Harel, M., McCarthy, A.A., Toker, L., Silman, I., Futerman, A.H. & Sussman, J.L. (2003) X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Reports, 4, 704-709.
32. Dweck, A., Abrahamov, A., Hadas-Halpern, I., Bdolach-Avram, T., Zimran, A. & Elstein, D. (2002) Type I Gaucher disease in children with and without enzyme therapy. Pediatric Hematology and Oncology, 19, 389-397.
33. Elstein, D., Klutstein, M.W., Lahad, A., Abrahamov, A., Hadas-Halpern, I. & Zimran, A. (1998) Echocardiographic assessment of pulmonary hypertension in Gaucher's disease. Lancet, 351, 1544-1546.
34. Erikson, A., Bembi, B. & Schiffmann, R. (1997) Neuronopathic forms of Gaucher's disease. In: Gaucher's Disease, Vol. 10 (ed. by A. Zimran), pp. 711-723. Bailliere Tindall, London.
35. Eto, Y., Shen, J.S., Meng, X.L. & Ohashi, T. (2004) Treatment of lysosomal storage disorders: cell therapy and gene therapy. Journal of Inherited Metabolic Disease, 27, 411-415.
36. Fan, J.Q. (2003) A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends in Pharmacological Science, 24, 355-360.
37. Florena, A.M., Franco, V. & Campesi, G. (1996) Immunophenotypical comparison of Gaucher's and pseudo-Gaucher cells. Pathology International, 46, 155-160.
38. Futerman, A.H. & Hannun, Y.A. (2004) The complex life of simple sphingolipids. EMBO Reports, 5, 777-782.
39. Futerman, A.H. & van Meer, G. (2004) The cell biology of lysosomal storage disorders. Nature Reviews Molecular Cell Biology, 5, 554-565.
40. Futerman, A.H., Sussman, J.L., Horowitz, M., Silman, I. & Zimran, A. (2004) New directions in the treatment of Gaucher disease. Trends in Pharmacological Sciences, 25, 147-151.
41. Gillis, S., Hyam, E., Abrahamov, A., Elstein, D. & Zimran, A. (1999) Platelet function abnormalities in Gaucher disease patients. American Journal of Hematology, 61, 103-106.
42. Ginzburg, L., Kacher, Y. & Futerman, A.H. (2004) The pathogenesis of glycosphingolipid storage disorders. Seminars in Cell and Developmental Biology, 15, 417-431.
43. Goker-Alpan, O., Schiffmann, R., Park, J.K., Stubblefield, B.K., Tayebi, N. & Sidransky, E. (2003) Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3. Journal of Pediatrics, 143, 273-276.
44. Gornati, R., Bembi, B., Tong, X., Boscolo, R. & Berra, B. (1998) Total glycolipid and glucosylceramide content in serum and urine of patients with Gaucher's disease type 3 before and after enzyme replacement therapy. Clinica Chimica Acta, 271, 151-161.
45. Gornati, R., Berra, B., Montorfano, G., Martini, C., Ciana, G., Ferrari, P., Romano, M. & Bembi, B. (2002) Glycolipid analysis of different tissues and cerebrospinal fluid in type II Gaucher disease. Journal of Inherited Metabolic Disease, 25, 47-55.
46. Grabowski, G.A. & Hopkin, R.J. (2003) Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annual Review of Genomics and Human Genetics, 4, 403-436.
47. Grabowski, G.A., Andria, G., Baldellou, A., Campbell, P.E., Charrow, J., Cohen, I.J., Harris, C.M., Kaplan, P., Mengel, E., Pocovi, M. & Vellodi, A. (2004) Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. European Journal of Pediatrics, 163, 58-66.
48. Grace, M.E., Newman, K.M., Scheinker, V., Berg-Fussman, A. & Grabowski, G.A. (1994) Analysis of human acid β-glucosidase by site-directed mutagenesis and heterologous expression. Journal of Biological Chemistry, 269, 2283-2291.
49. Hakozaki, H., Takahashi, K., Naito, M., Kojima, M., Koizumi, Y. & Ninomiya, N. (1979) Gaucher-like cells in juvenile GM1-gangliosidosis and in beta-thalassemia - a histochemical and ultrastructural observation. Acta Pathologica Japonica, 29, 303-318.
50. Ham, D. (2003) Structural requirements for lysosomal targeting of the prosaposin precursor protein. Cell Biology International, 27, 675-687.
51. Heitner, R., Elstein, D., Aerts, J., Weely, S. & Zimran, A. (2002) Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells, Molecules and Diseases, 28, 127-133.
52. Hollak, C.E., van Weely, S., van Oers, M.H. & Aerts, J.M. (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. Journal of Clinical Investigation, 93, 1288-1292.
53. Hollak, C.E., Evers, L., Aerts, J.M. & van Oers, M.H. (1997a) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells, Molecules and Diseases, 23, 201-212.
54. Hollak, C.E., Levi, M., Berends, F., Aerts, J.M. & van Oers, M.H. (1997b) Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. British Journal of Haematology, 96, 470-476.
55. Hong, Y.B., Kim, E.Y., Yoo, H.W. & Jung, S.C. (2004) Feasibility of gene therapy in Gaucher disease using an adeno-associated virus vector. Journal of Human Genetics, 49, 536-543.
56. Horowitz, M. & Zimran, A. (1994) Mutations causing Gaucher disease. Human Mutation, 3, 1-11.
57. Kim, E.Y., Hong, Y.B., Lai, Z., Kim, H.J., Cho, Y.H., Brady, R.O. & Jung, S.C. (2004) Expression and secretion of human glucocerebrosidase mediated by recombinant lentivirus vectors in vitro and in vivo: implications for gene therapy of Gaucher disease. Biochemical and Biophysical Research Communications, 318, 381-390.
58. Kinnear, N.P., Boittin, F.X., Thomas, J.M., Galione, A. & Evans, A.M. (2004) Lysosome-sarcoplasmic reticulum junctions: A trigger zone for calcium signalling by NAADP and endothelin-1. Journal of Biological Chemistry, 279, 54319-54326.
59. Korkotian, E., Schwarz, A., Pelled, D., Schwarzmann, G., Segal, M. & Futerman, A.H. (1999) Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. Journal of Biological Chemistry, 274, 21673-21678.
60. Krivit, W., Peters, C. & Shapiro, E.G. (1999) Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Current Opinion in Neurology, 12, 167-176.
61. Lachmann, R.H. (2003) Miglustat. Oxford GlycoSciences/Actelion. Current Opinion in Investigational Drugs, 4, 472-479.
62. Lachmann, R.H., Grant, I.R., Halsall, D. & Cox, T.M. (2004) Twin pairs showing discordance of phenotype in adult Gaucher's disease. Quarterly Journal of Medicine, 97, 199-204.
63. Lin, H., Sugimoto, Y., Ohsaki, Y., Ninomiya, H., Oka, A., Taniguchi, M., Ida, H., Eto, Y., Ogawa, S., Matsuzaki, Y., Sawa, M., Inoue, T., Higaki, K., Nanba, E., Ohno, K. & Suzuki, Y. (2004) N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease. Biochimica et Biophysica Acta, 1689, 219-228.
64. Lloyd-Evans, E., Pelled, D., Riebeling, C., Bodennec, J., de-Morgan, A., Waller, H., Schiffmann, R. & Futerman, A.H. (2003) Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. Journal of Biological Chemistry, 278, 23594-23599.
65. Lwin, A., Orvisky, E., Goker-Alpan, O., LaMarca, M.E. & Sidransky, E. (2004) Glucocerebrosidase mutations in subjects with parkinsonism. Molecular Genetics and Metabolism, 81, 70-73.
66. Meivar-Levy, I., Horowitz, M. & Futerman, A.H. (1994) Analysis of glucocerebrosidase activity using N-(1-[14C]hexanoyl)-D- erythroglucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease. Biochemical Journal, 303, 377-382.
67. Mistry, P.K., Sirrs, S., Chan, A., Pritzker, M.R., Duffy, T.P., Grace, M.E., Meeker, D.P. & Goldman, M.E. (2002) Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Molecular Genetics and Metabolism, 77, 91-98.
68. Moller, H.J., de Post, M., Aerts, H., Hollak, C. & Moestrup, S.K. (2004) Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease. European Journal of Haematology, 72, 135-139.
69. Moran, M.T., Schofield, J.P., Hayman, A.R., Shi, G.P., Young, E. & Cox, T.M. (2000) Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood, 96, 1969-1978.
70. Naito, M., Takahashi, K. & Hojo, H. (1988) An ultrastructural and experimental study on the development of tubular structures in the lysosomes of Gaucher cells. Laboratory Investigation, 58, 590-598.
71. Neufeld, E.F. (1991) Lysosomal storage diseases. Annual Review of Biochemistry, 60, 257-280.
72. Nilsson, O., Mansson, J.E., Hakansson, G. & Svennerholm, L. (1982a) The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of Gaucher's disease. Biochimica and Biophysica Acta, 712, 453-463.
73. Nilsson, O., Hakansson, G., Dreborg, S., Groth, G.G. & Svennerholm, L. (1982b) Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III. Clinical Genetics, 22, 274-279.
74. Orvisky, E., Park, J.K., LaMarca, M.E., Ginns, E.I., Martin, B.M., Tayebi, N. & Sidransky, E. (2002) Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Molecular Genetics and Metabolism, 76, 262-270.
75. Parkin, J. & Brunning, R. (1982) Pathology of the Gaucher cell. In: Gaucher Disease: A Century of Delineation and Research (ed. by R. Desnick, S. Gatt & G. Grabowski), p. 151. Alan R. Liss, New York.
76. Pastores, G.M., Weinreb, N.J., Aerts, H., Andria, G., Cox, T.M., Giralt, M., Grabowski, G.A., Mistry, P.K. & Tylki-Szymanska, A. (2004) Therapeutic goals in the treatment of Gaucher disease. Seminars in Hematology, 41, 4-14.
77. Pelled, D., Trajkovic-Bodennec, S., Lloyd-Evans, E., Sidransky, E., Schiffmann, R. & Futerman, A.H. (2004) Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiology of Disease (in press).
78. Pennelli, N., Scaravilli, F. & Zacchello, F. (1969) The morphogenesis of Gaucher cells investigated by electron microscopy. Blood, 34, 331-347.
79. Perez Calvo, J.I., Inigo Gil, P., Giraldo Castellano, P., Torralba Cabeza, M.A., Civeira, F., Lario Garcia, S., Pocovi, M. & Lara Garcia, S. (2000) Transforming growth factor beta (TGF-beta) in Gaucher's disease. Preliminary results in a group of patients and their carrier and non-carrier relatives. Medicina Clinica, 115, 601-604.
80. Platt, F.M., Neises, G.R., Reinkensmeier, G., Townsend, M.J., Perry, V.H., Proia, R.L., Winchester, B., Dwek, R.A. & Butters, T.D. (1997) Prevention of lysosomal storage disease in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science, 276, 428-431.
81. Renkema, G.H., Boot, R.G., Strijland, A., Donker-Koopman, W.E., van den Berg, M., Muijsers, A.O. & Aerts, J.M. (1997) Synthesis, sorting, and processing into distinct isoforms of human macrophage chitotriosidase. European Journal of Biochemistry, 244, 279-285.
82. Rijnboutt, S., Aerts, H.M., Geuze, H.J., Tager, J.M. & Strous, G.J. (1991) Mannose 6-phosphate-independent membrane association of cafhepsin D, glucocerebrosidase, and sphingolipid-activating protein in HepG2 cells. Journal of Biological Chemistry, 266, 4862-4868.
83. Ringden, O., Groth, G.G., Erikson, A., Granqvist, S., Mansson, J.E. & Sparrelid, E. (1995) Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation, 59, 864-870.
84. Rudensky, B., Paz, E., Altarescu, G., Raveh, D., Elstein, D. & Zimran, A. (2003) Fluorescent flow cytometric assay: a new diagnostic tool for measuring beta-glucocerebrosidase activity in Gaucher disease. Blood Cells, Molecules and Diseases, 30, 97-99.
85. Sa Miranda, M.C., Aerts, J.M., Pinto, R., Fontes, A., de Lacerda, L.W., van Weely, S., Barranger, J. & Tager, J.M. (1990) Activity of glucocerebrosidase in extracts of different cell types from type 1 Gaucher disease patients. Clinical Genetics, 38, 218-227.
86. Sabatini, D.D. & Adesnik, M.B. (eds) (2001) The biogenesis of membranes and organelles. In: The Metabolic and Molecular Basis of Inherited Disease (ed. by C.R. Scriver, W.S. Sly, B. Childs, A.L. Beaudet, D. Valle, K.W. Kinzler & B. Volgelstein), Vol II, pp. 433-517. McGraw-Hill, Columbus, USA.
87. Samuel, R., Katz, K., Papapoulos, S.E., Yosipovitch, Z., Zaizov, R. & Liberman, U.A. (1994) Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease. Pediatrics, 94, 385-389.
88. Sawkar, A.R., Cheng, W.C., Beutler, E., Wong, C.H., Balch, W.E. & Kelly, J.W. (2002) Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America, 99, 15428-15433.
89. Schiffmann, R., Mankin, H., Dambrosia, J.M., Xavier, R.J., Kreps, C., Hill, S.C., Barton, N.W. & Rosenthal, D.I. (2002) Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells, Molecules and Diseases, 28, 288-296.
90. Sly, W.S. (2004) Enzyme replacement therapy for lysosomal storage disorders: successful transition from concept to clinical practice. Missouri Medicine, 101, 100-104.
91. Suzuki, K. (1998) Twenty-five years of the 'psychosine hypothesis': a personal perspective of its history and present status. Neurochemical Research, 23, 251-259.
92. Svennerholm, L., Hakansson, G. & Dreborg, S. (1980) Assay of the beta-glucosidase activity with natural labelled and artificial substrates in leukocytes from homozygotes and heterozygotes with the Norrbottnian type (type 3) of Gaucher disease. Clinica Chimica Acta, 106, 183-193.
93. Svennerholm, L., Mansson, J.E. & Rosengren, B. (1986) Cerebroside-beta-glucosidase activity in Gaucher brain. Clinical Genetics, 30, 131-135.
94. Tessitore, A., del Martin, M.P., Sano, R., Ma, Y., Mann, L., Ingrassia, A., Laywell, E.D., Steindler, D.A., Hendershot, L.M. & d'Azzo, A. (2004) GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Molecular Cell, 15, 753-766.
95. Toyras, A., Ollikainen, J., Taskinen, M. & Monkkonen, J. (2003) Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro. European Journal of Pharmaceutical Sciences, 19, 223-230.
96. Trajkovic-Bodennec, S., Bodennec, J. & Futerman, A.H. (2004) Phosphatidylcholine metabolism is altered in a monocyte-derived macrophage model of Gaucher disease but not in lymphocytes. Blood Cells, Molecules and Diseases, 33, 77-82.
97. Tsai, P., Lipton, J.M., Sahdev, I., Najfeld, V., Rankin, L.R., Slyper, A.H., Ludman, M. & Grabowski, G.A. (1992) Allogenic bone marrow transplantation in severe Gaucher disease. Pediatric Research, 31, 503-507.
98. Vaccaro, A.M., Salvioli, R., Tatti, M. & Ciaffoni, F. (1999) Saposins and their interaction with lipids. Neurochemical Research, 24, 307-314.
99. Vellodi, A., Bembi, B., de Villemeur, T.B., Collin-Histed, T., Erikson, A., Mengel, E., Rolfs, A. & Tylki-Szymanska, A. (2001) Management of neuronopathic Gaucher disease: a European consensus. Journal of Inherited Metabolic Disease, 24, 319-327.
100. Weinreb, N.J., Charrow, J., Andersson, H.C., Kaplan, P., Kolodny, E.H., Mistry, P., Pastores, G., Rosenbloom, B.E., Scott, C.R., Wappner, R.S. & Zimran, A. (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. American Journal of Medicine, 113, 112-119.
101. Weinreb, N.J., Aggio, M.C., Andersson, H.C., Andria, G., Charrow, J., Clarke, J.T., Erikson, A., Giraldo, P., Goldblatt, J., Hollak, C., Ida, H., Kaplan, P., Kolodny, E.H., Mistry, P., Pastores, G.M., Pires, R., Prakesh-Cheng, A., Rosenbloom, B.E., Scott, C.R., Sobreira, E., Tylki-Szymanska, A., Vellodi, A., vom Dahl, S., Wappner, R.S. & Zimran, A. (2004) Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Seminars in Hematology, 41, 15-22.
102. Wenstrup, R.J., Bailey, L., Grabowski, G.A., Moskovitz, J., Oestreich, A.E., Wu, W. & Sun, S. (2004) Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood, 104, 1253-1257.
103. Wong, K., Sidransky, E., Verma, A., Mixon, T., Sandberg, G.D., Wakefield, L.K., Morrison, A., Lwin, A., Colegial, C., Allman, J.M. & Schiffmann, R. (2004) Neuropathology provides clues to the pathophysiology of Gaucher disease. Molecular Genetics and Metabolism, 82, 192-207.
104. Young, E., Chatterton, C., Vellodi, A. & Winchester, B. (1997) Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplantation or by enzyme replacement therapy with alglucerase. Journal of Inherited Metabolic Disease, 20, 595-602.
105. Zhao, H. & Grabowski, G.A. (2002) Gaucher disease: Perspectives on a prototype lysosomal disease. Cell Molecular and Life Sciences, 59, 694-707.
106. Zhu, Y., Li, X., Schuchman, E.H., Desnick, R.J. & Cheng, S.H. (2003) Dexamethasone-mediated upregulation of the mannose receptor improves the delivery of recombinant glucocerebrosidase to gaucher macrophages. Journal of Pharmacology and Experimental Therapeutics, 308, 705-711.
107. Zimran, A. (ed.) (1997) Gaucher's Disease. Balliere Tindall, Cambridge, UK.
108. Zimran, A. & Elstein, D. (2003) Gaucher disease and the clinical experience with substrate reduction therapy. Philosophical Transactions of the Royal Society of London, 358, 961-966.
109. Zimran, A., Sorge, J., Gross, E., Kubitz, M., West, C. & Beutler, E. (1989) Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet, 2, 349-352.